

NC MEDI-CAPS LIMITED

Regd. Office & Works :

Mhow-Neemuch Road, Sector-1,
Pithampur - 454775, Distt. Dhar,
Madhya Pradesh, INDIA

CIN-L24232MP1983PLC002231

Phone : + 91-7292-424242
Fax. : + 91-7292-407387
E-mail : info@medicaps.com
sales@medicaps.com
Website : www.medicaps.com

MEDICAPS/SE/18-19

Date:- 27th June, 2018

Online filing at: www.listing.bseindia.com

To
The General Manager
DCS-CRD
BSE Limited.
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort MUMBAI - 400001(MH)

BSE Scrip Code: 523144

Subject: Submission of the Revised Audited Standalone and Consolidated Financial Results along with the Auditors' Report and Reconciliation Statement of Equity for the quarter/year ended 31st March, 2018 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir,

This letter is in reference with the Email dated 22nd June, 2018 regarding discrepancy in the Financial Results for the year ended 31st March, 2018 under Regulations 33(3)(b) of SEBI (LODR) Regulations, 2015

Further pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Revised Audited Standalone and Consolidated Financial Results along with the Auditors' Report thereon by Statutory Auditors and Reconciliation Statement of Equity for the quarter/year ended 31st March 2018 in the PDF Format.

We are also in the process to file the aforesaid Revised Financial Results in the XBRL form and the same shall also be hosted at the website of the Company.

You are requested to please take on record the aforesaid Revised Audited Standalone and Consolidated Financial Results along with Auditor's Report and Reconciliation Statement of Equity for your records and reference.

Thanking You,
Yours Faithfully,
For, MEDI-CAPS LTD.



AYUSHI SILOT
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl: Revised Audited Standalone and Consolidated Financial Result.

Indore Office :

201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)
Telefax No. : +91-731-4046321, 4041435, 4028148

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Fax : 4215397, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (LODR) Regulations, 2015.

To Board of Directors of
MEDICAPS LTD.

We have audited the quarterly financial results of **MEDICAPS LTD.** for the quarter ended 31st March 2018 and year to date results for the period 01.04.2017 to 31.03.2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared from interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25/Ind AS 34), mandated under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.


In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/loss and other financial information for the quarter ended 31st March 2018 as well as the year to date results for the period from 01st April 2017 to 31st March 2018.

Place: Indore
Date: 28/05/2018

For: Rawka & Associates
(Chartered Accountants)




Venus Rawka
(Partner)
M. No. 429040
F. R. No. 021606C

RAWKA & ASSOCIATES

CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Fax : 4215397, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com, cprawka@gmail.com

Independent Auditor's Report On Consolidated Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (LODR) Regulations, 2015.

To Board of Directors of
MEDICAPS LTD.


We have audited the quarterly consolidated financial results of **MEDICAPS LTD.** for the quarter ended 31st March 2018, being submitted by the company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (LODR) Regulations, 2015. These financial results which are the responsibility of the company's management and approved by Board of Directors, have been prepared on the basis of related financial statements which is in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on these financial results.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by Management, as well as evaluating the overall presentation of the financial results. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a reasonable basis for our opinion.


In our opinion and to the best of our information and according to the explanations given to us these consolidated financial results as well as year to date results:

- (i) Include the year to date financial results of Medgel Pvt. Ltd.
- (ii) have been presented in accordance with the requirements of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (LODR) Regulations, 2015 in this regard; and
- (iii) give a true and fair view of the consolidated net profit/loss and other financial information for the consolidated year to date results for the period from 01st April 2017 to 31st March 2018.

Place: Indore
Date: 28/05/2018



For: Rawka & Associates
(Chartered Accountants)



Venus Rawka
(Partner)
M. No. 429040
F. R. No. 021606C

MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-424242, Fax: 07292-407387
 Website: www.medicaps.com Email: investors@medicaps.com CIN: L24232MP1983PLC002231
 STANDALONE/CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31ST MARCH 2018

PART I

Sr. No.	Particulars	Standalone						Consolidated	
		3 Months ended on			Year Ended			Year Ended	
		31.03.2018 (Audited)	31.12.2017 (Unaudited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)	
I	Income from operations								
	(a) Net sales	530.76	593.57	513.51	2235.35	2275.71	4967.52	4403.82	
	(b) Other operating income	28.38	14.12	26.65	65.74	56.85	89.31	75.98	
	Total Income from operations	559.14	607.69	540.16	2301.09	2332.56	5056.84	4479.80	
II	Other Income	1.57	0.00	21.49	1.55	56.44	17.90	126.64	
III	Total income (I+II)	560.71	607.69	561.65	2302.65	2389.00	5074.74	4606.43	
IV	Expenses								
	a) Cost of material consumed	248.28	211.22	191.81	879.10	1015.84	2464.78	2183.77	
	b) Purchase of stock in trade	0.00	0.09	0.00	10.41	9.77	10.41	9.77	
	c) Changes in Inventories of finished goods, & work in progress	(75.01)	83.39	0.31	128.04	23.17	226.40	70.71	
	d) Employee benefits expense	152.90	106.31	127.24	505.16	508.94	875.87	874.27	
	e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.66	1.34	
	f) Power Cost	84.05	93.40	83.71	344.02	325.86	515.49	458.54	
	g) Depreciation expense	(14.87)	16.24	15.99	33.87	36.64	179.25	180.89	
	h) Other expenses	136.38	79.99	118.64	325.67	317.74	667.11	655.02	
	Total Expenses (IV)	531.72	590.65	537.70	2226.28	2237.96	4939.96	4434.31	
V	Profit (Loss) before exceptional items and tax (III-IV)	28.99	17.04	23.95	76.37	151.04	134.77	172.12	
VI	Exceptional items	0	0	0	0	0	0	0	
VII	Profit (Loss) before extra-ordinary items and tax (V-VI)	28.99	17.04	23.95	76.37	151.04	134.77	172.12	
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
IX	Profit (Loss) after extra-ordinary items but before tax (VII-VIII)	28.99	17.04	23.95	76.37	151.04	134.77	172.12	
X	Tax expense								
	a) Current Tax	6.00	4.00	5.33	18.00	33.00	18.00	33.00	
	b) Deferred Tax	2.02	0.00	0	2.02	2.33	2.02	2.33	
	Total Tax Expenses	8.02	4.00	5.33	20.02	35.33	20.02	35.33	
XI	Profit (+)/Loss (-) for the period from continuing operations (IX-X)	20.97	13.04	18.61	56.35	115.71	114.75	136.79	
XII	Profit / (Loss) from Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XIII	Tax expenses from Discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XIV	Profit / (Loss) from Discontinuing operations (after tax (XII-XIII))	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XV	Profit / (Loss) for the period (XI+XIV)	20.97	13.04	18.61	56.35	115.71	114.75	136.79	
XVI	Other Comprehensive Income:								
	A (i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	B (i) Items that will be re-classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
XVII	Total Comprehensive Income for the period (XV + XVI) (Comprising profit/(Loss) & other comprehensive income for the period)	20.97	13.04	18.61	56.35	115.71	114.75	136.79	
XVIII	Paid up Equity Share Capital (Face Value of Rs. 10/- each)	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00	
XIX	Reserve excluding revaluation reserve as per balance sheet of previous accounting year				5444.66	5390.49	7774.64	7662.07	
XX	Earnings Per Share (for continuing operations)								
	(a) Basic	0.17	0.10	0.15	0.45	0.93	0.92	1.10	
	(b) Diluted	0.17	0.10	0.15	0.45	0.93	0.92	1.10	




XXI	Earnings Per Share (for Discontinued operations)						
	(a) Basic		0.00	0.00	0.00	0.00	0.00
	(b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XXII	Earnings Per Share (for Discontinued and continuing operations)						
	(a) Basic						
	(b) Diluted	0.17	0.10	0.15	0.45	0.93	1.10
		0.17	0.10	0.15	0.45	0.93	0.92
							1.10

2 Statement of Assets and Liabilities as on 31.03.2018

Particulars		Standalone		Consolidated	
		31.03.2018	31.03.2017	31.03.2018	31.03.2017
ASSETS					
(I)	Non-current assets				
	(a) Property, Plant and Equipment				
	(b) Financial Assets	393.40	387.59	5995.00	6105.58
	(i) Investments				
	(c) Other non-current assets	4571.85	4531.58	309.50	249.23
	Sub-total - Non-current assets	44.26	40.94	75.70	77.39
		5009.51	4960.11	6380.20	6432.19
(2)	Current assets				
	(a) Inventories				
	(b) Financial Assets	576.18	760.34	1016.01	1322.30
	(i) Investments				
	(ii) Trade receivables	516.69	505.12	916.61	641.30
	(iii) Cash and cash equivalents	694.07	605.63	1303.49	894.09
	(c) Other current assets	204.35	197.19	232.35	212.68
	Sub-total - Current assets	181.11	172.50	242.01	235.06
		2172.40	2240.78	3710.47	3305.50
	TOTAL - ASSETS	7181.92	7200.89	10090.68	9737.68
A EQUITY AND LIABILITIES					
EQUITY					
	(a) Equity Share Capital				
	(b) Other Equity	1247.00	1247.00	1247.00	1247.00
	Total Equity	5444.66	5390.49	7774.64	7662.07
LIABILITIES					
(1)	Non-Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings				
	(b) Provisions	0.00	0.00	0.00	9.11
	(c) Deferred tax liabilities (Net)	119.54	105.14	119.54	105.14
	(d) Other Non-Current Liabilities	40.71	38.70	40.71	38.70
	Sub-total - Non-current liabilities	0.00	0.00	0.00	0.00
		160.25	143.83	160.25	152.94
(2)	Current Liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	17.46	0.00	17.46	0.00
	(ii) Trade payables	147.48	224.50	623.54	434.83
	(b) Other current liabilities	147.07	162.08	249.78	207.85
	(c) Current Tax Liabilities (Net)	18.00	33.00	18.00	33.00
	Sub-total - Current liabilities	330.01	419.58	908.78	675.68
	TOTAL - EQUITY AND LIABILITIES	7181.92	7200.89	10090.68	9737.68

Notes:


- The above results have been reviewed by the Audit Committee and approved by the Board of Director at their meetings held on 28th May, 2018.
- The IND AS compliant financial results for the quarter ended March 31, 2017 have been reviewed by the Statutory Auditors and are the balancing figures between the audited figures in respect of the full financial year and the year to date figures upto the 03rd Quarter which was subject to Limited Review by the Auditors.
- The Company has adopted Companies (Indian Accounting Standards) Rules, 2015 (IND AS) from 01st April, 2017 and accordingly this financial results have been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 interim financial reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules made there under.
- The Company is dealing only in one segment.




5. The Government of India introduced the Goods and Service tax (GST) with effect from 1st July 2017 which subsumes excise duty and various other Indirect taxes. As required under Ind AS 18, revenue for the quarter ended 31st March 2018 and 31st December 2017 are reported net of GST. The revenue for the year ended 31st March 2018 includes excise duty up to 30th June 2017. Accordingly, Income from operations for the quarter and year ended 31st March 2018 are not comparable with corresponding previous periods.
6. Previous period figures have been regrouped and rearranged wherever necessary to confirm to this period classification as per requirement.
7. Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2017-18 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on March 31, 2018, therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion.
8. Reconciliation of net Profit as previously reported on account of transition from the previous Accounting Standard (AS) to Indian Accounting Standard (IND AS) for the quarter & year ended 31st March, 2017 as under:

PARTICULARS	Quarter	Year ended
	ended 31.03.2017	31.03.2017
Net Profit for the period under previous AS		
Add/(Less): Impact	18.61	115.71
Profit after tax as reported under IND AS	0	0
Other Comprehensive Income	18.61	115.71
Total Comprehensive Income as reported under IND AS	0	0
	18.61	115.71

Place : Pithampur
Date : 28/05/2018




For MEDI CAPS LIMITED

 Anil K. Garg
 Managing Director
 DIN: 00274321

Reconciliation of Equity as previously reported under AS and as per Ind AS is summarized below:

(Rs. in Lakhs)

Particulars	Standalone Year Ended 31 st March, 2017	Consolidated Year Ended 31 st March, 2017
Other Equity as per previous AS	5390.49	7662.07
Adjustments:	NIL	NIL
Net other Equity as per IND AS	5390.49	7662.07



NC MEDI-CAPS LIMITED

Regd. Office & Works :

Mhow-Neemuch Road, Sector-1,
Pithampur- 454 775, Distt. Dhar,
Madhya Pradesh, INDIA

CIN : L24232MP1983PLC002231

Phone : + 91-7292-424242
Fax : + 91-7292-407387
E-mail : info@medicaps.com
sales@medicaps.com
investors@medicaps.com
Website : www.medicaps.com

MEDICAPS/SE/2018-19

Online filing at: www.listing.bseindia.com

28th May, 2018

To
The General Manager
DCS-CRD
BSE Ltd.
PhirozeJeejeebhoy Towers
Dalal Street, Fort MUMBAI-400001(MH)

BSE Scrip Code: 523144

Subject: Submission of declaration as per second proviso to the Regulation 33(3)(d) of SEBI (LODR) Regulation, 2015 for the Annual Audited Standalone and Consolidated Financial Results for the Year ended 31st March, 2018.

Dear Sir/Madam,


We hereby submit the following declaration regarding unmodified Auditors' reports on the Audited Standalone and Consolidated Financial Results/Statements for the year ended 31st March, 2018 as audited by the Auditors of the Company.


DECLARATION

Pursuant to SEBI (LODR) Regulations, 2015 and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25th May, 2016 and further amendment, therein vide SEBI Circular No.CIR/CFD/CMD/56/2016 dated 27th May, 2016. We the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of the company for the financial year ended on 31st March, 2018, the auditor does not express any modified opinion(s)/ audit qualification(s)/ or other reservation(S) and accordingly the statement on impact of audit qualification is not required to be given in the Annexure 1..


You are requested to please consider and take on record the same.

Thanking You,
Yours Faithfully,
For, MEDICAPS LTD.


MAHESH KUMAR PATNI
CHAIRMAN OF THE MEETING
DIN 07444248




MANISH KUMAR JAIN
CHIEF FINANCIAL OFFICER



Indore Office :

201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)
Telefax No. : +91-731-4046321, 4041435, 4028148

Regd. Office & Works :
Mhow-Neemuch Road, Sector-1,
Pithampur- 454 775, Distt. Dhar,
Madhya Pradesh, INDIA

CIN : L24232MP1983PLC002231

Phone : + 91-7292-424242
Fax. : + 91-7292-407387
E-mail : info@medicaps.com
sales@medicaps.com
investors@medicaps.com
Website : www.medicaps.com

MEDICAPS/SE/2018-19

28th May, 2018

Online filing at: www.listing.bseindia.com

To
The General Manager
DCS-CRD
BSE Ltd.
PhirozeJeejeebhoy Towers
Dalal Street, Fort MUMBAI-400001(MH)

BSE Scrip Code: 523144

Subject: Intimation regarding company opts to submit quarterly/year to date Unaudited Standalone Financial Results as per Regulation 33(3)(b) of SEBI(LODR) Regulations 2015.


Dear Sir,

With reference to the captioned subject, kindly note that in terms of the Regulation 33(3)(b)(i) of SEBI(LODR) Regulations 2015, the company is having a material subsidiary and as per the regulations of SEBI (LODR) Regulations, 2015 the company will submit unaudited quarterly results on Standalone Basis for the financial year 2018-19 and in the last Quarter i.e. starting from 01/01/2019 to 31/03/2019 the company will submit Consolidated Financial Results for the year to date figure to the Stock Exchange.

This option shall not be changed during the financial year 2018-19.

You are requested to please take on record the same.

Thanking You,
Yours Faithfully,
For, **MEDI-CAPS LTD.**


AYUSHI SLOT
COMPANY SECRETARY &
COMPLIANCE OFFICER



Indore Office :

201, Pushpratna Paradise, 9/5, New Palasia, Indore 452 001 (INDIA)

Telefax No. : +91-731-4046321, 4041435, 4028148